Bucladesine (sodium)

• UNSPSC Description:

  Bucladesine sodium salt (Dibutyryl-cAMP sodium salt) is a stabilized cyclic AMP (cAMP) analog and a selective PKA activator. Bucladesine sodium salt raises the intracellular levels of cAMP. Bucladesine sodium salt is also a phosphodiesterase (PDE) inhibitor. Bucladesine sodium salt has anti-inflammatory activity and can be used for impaired wound healing[1][2][3][4].

• Target Antigen:

  Phosphodiesterase (PDE); PKA

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease;Stem Cell/Wnt;TGF-beta/Smad

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/Bucladesine-sodium-salt.html

• Purity:

  99.48

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)|H2O : ≥ 100 mg/mL

• Smiles:

  O=C(CCC)O[C@H]1[C@H](N2C(N=CN=C3NC(CCC)=O)=C3N=C2)O[C@@](CO4)([H])[C@@]1([H])OP4(O[Na])=O

• Molecular Weight:

  491.37

• References & Citations:

  [1]Sharifzadeh, M., et al., Post-training intrahippocampal infusion of nicotine-bucladesine combination causes a synergistic enhancement effect on spatial memory retention in rats. Eur J Pharmacol, 2007. 562(3): p. 212-20.|[2]Mafune, E., M. Takahashi, and N. Takasugi, Effect of vehicles on percutaneous absorption of bucladesine (dibutyryl cyclic AMP) in normal and damaged rat skin. Biol Pharm Bull, 1995. 18(11): p. 1539-43.|[3]Rundfeldt, C., et al., The stable cyclic adenosine monophosphate analogue, dibutyryl cyclo-adenosine monophosphate (bucladesine), is active in a model of acute skin inflammation. Arch Dermatol Res, 2012.|[4]Salehi F, et al. Effect of bucladesine, pentoxifylline, and H-89 as cyclic adenosine monophosphate analog, phosphodiesterase, and protein kinase A inhibitor on acute pain. Fundam Clin Pharmacol. 2017 Aug;31(4):411-419.|[5]Shimojo M, et al. The cholinergic gene locus is coordinately regulated by protein kinase A II in PC12 cells. J Neurochem. 1998 Sep;71(3):1118-26.Adv Sci (Weinh). 2021 Oct 31;e2100808.|bioRxiv. 2024 Mar 31.|Cell Commun Signal. 2022 Apr 12;20(1):52.|Cell Stem Cell. 2021 Aug 5;28(8):1362-1379.e7.|Cell Tissue Res. 2022 Feb 11.|Cells. 2024 Jul 26;13(15):1260.|Ecotoxicol Environ Saf. 2022 Aug 17;243:113982.|Eur J Pharmacol. 2022 Aug 28;932:175231.|FASEB J. 2020 Oct;34(10):13376-13395.|FASEB J. 2024 May 15;38(9):e23622.|FEBS Lett. 2021 Oct 23.|Front Microbiol. 2021 Aug 17;12:692693.|Int J Biol Sci. 2024 Aug 19;20(11):4476-4495.|Int J Mol Sci. 2022, 23(20), 12595.|Int J Mol Sci. 2023 Feb 8;24(4):3398.|Int J Mol Sci. 2023 Mar 7.|J Assist Reprod Genet. 2024 Mar 25.|J Bone Miner Metab. 2021 Apr 8.|J Endocrinol. 2019 Sep 1;JOE-19-0284.R2.|J Steroid Biochem Mol Biol. 24 September 2022, 106192.|Pigment Cell Melanoma Res. 2023 Aug 9.|Plants. 2023 Oct 24, 12(21), 3666.|Proteome Sci. 2023 Oct 11;21(1):16.|protocols.io. 2024 Jan 12.|Reproduction. 2021 May 27;162(1):33-45.|Res Sq. 2024 Jun 11.|Toxins. 2021 Aug 22;13(8):585.|Exp Ther Med. January 31, 2022.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Clinical Information:

  Launched

• CAS Number:

  16980-89-5